These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15268666)

  • 21. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
    Schiff MH
    Drugs; 2004; 64(22):2493-501. PubMed ID: 15516150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study.
    Omdal R; Gunnarsson R
    Rheumatol Int; 2005 Aug; 25(6):481-4. PubMed ID: 15071755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recommendations of the Deutschen Gesellschaft für Rheumatologie on therapy of rheumatoid arthritis with the interleukin-1-receptor-antagonist Akakinra (KINERET)].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):698-700. PubMed ID: 12491134
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
    Bresnihan B
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii74-7. PubMed ID: 12379629
    [No Abstract]   [Full Text] [Related]  

  • 26. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.
    Bresnihan B
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S32-4. PubMed ID: 14989427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The trials of anakinra.
    Burls A; Jobanputra P
    Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.
    Hallegua DS; Weisman MH
    Ann Rheum Dis; 2002 Nov; 61(11):960-7. PubMed ID: 12379516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].
    Suzuki T
    Nihon Rinsho; 2002 Dec; 60(12):2397-400. PubMed ID: 12510368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.
    Østergaard M; Duer A; Nielsen H; Johansen JS; Narvestad E; Ejbjerg BJ; Baslund B; Møller JM; Thomsen HS; Petersen J
    Ann Rheum Dis; 2005 Oct; 64(10):1503-6. PubMed ID: 15778238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing the safety of anakinra in patients with rheumatoid arthritis.
    Fleischmann RM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii29-35. PubMed ID: 12817093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB; Strand V; Aguilar D; Ofman JJ
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
    Fleischmann RM; Iqbal I; Stern RL
    Expert Opin Drug Saf; 2004 Sep; 3(5):391-403. PubMed ID: 15335295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist].
    Wendling D; Jorgensen C
    Rev Med Interne; 2002 Dec; 23(12):1006-11. PubMed ID: 12504237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
    Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
    Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
    [No Abstract]   [Full Text] [Related]  

  • 39. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.
    den Broeder AA; de Jong E; Franssen MJ; Jeurissen ME; Flendrie M; van den Hoogen FH
    Ann Rheum Dis; 2006 Jun; 65(6):760-2. PubMed ID: 16269431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of new biologicals in the treatment of rheumatoid arthritis.
    Weaver AL
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii17-iii23. PubMed ID: 15150428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.